For the second year in a row, Medimix International has been recognized by the PharmaTech Outlook magazine as among the TOP 10 companies for 2019 providing analytics solutions to Pharma and LifeScience companies in Europe.
The company’s diversified blue-chip customer base includes eight of the top 10 largest pharmaceutical companies in the world.
Impacting the Marketplace with RWD
Medimix has been providing robust RWD with its syndicated LiveTrackerTM series for indications in oncology, hematology, immunology, cardio-metabolism and diabetes, providing insights that help pharma companies understand the market landscape for their products and provide them with details on the patient treatment journey.
Medimix’s primary solution, LiveTracker™, is a cloud-based platform that provides real-time monitoring of clients’ therapeutic markets and drugs via key performance indicators and real-world data. It is unique in its ability to provide robust and comparable real-world evidence in more than 60 countries, including information on market structure, drug awareness and level of adoption, patient profiles, and treatment sequencing and outcomes.
Medimix developed the cloud-based LiveTrackerTM platform to gather global, real-world evidence (RWE) from Electronic Medical Records on a continuous basis and standardizes the information across systems and countries, making consolidation of global data possible. Leveraging real-world evidence (RWE) and real-world data (RWD) has proved to be a crucial advantage in clinical trials, R&D and marketing. It offers a unified view of the performance of drugs locally as well as globally.
Connecting the Dots for Multiple Departments
The multi-module tool furnishes vital and precise information for a variety of pharma departments, including Forecasting, Marketing, Strategy, Licensing, Market Access , HEOR, and Business Intelligence. The strategic insights provided are an invaluable aid to companies making decisions on developing more efficacious and cost-efficient drugs.
TO READ More HTML Link
For more information, visit www.medimix.net.